Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise
<p>LONDON, Sept. 30, 2026 /PRNewswire/ -- Clarenta today announced that Leads To Development (L2D) has joined Clarenta Group following a majority investment, strengthening Clarenta's ability to support biotech and pharmaceutical sponsors from preclinical drug development strategy through...</p>
Read original article ↗
Related Articles
LONG-LASTING TOUGHBOOK G3 SETS NEW STANDARDS FOR RUGGED TABLETS
Unrivalled battery life, increased mobility, and edge AI processing makes the G3 the only choice for accessing critical
- Nuvoton presenta el KA85010UA, un circuito integrado de monitorización de baterías de 26 celdas de sexta generación co
Sophia Space and Redwire Team Up to Advance Orbital Data Center Infrastructure
Companies sign MOU to explore collaboration on deployable structures, spacecraft integration and scalable architectures
AMD's Lisa Su reportedly revisiting South Korea in October to deepen HBM4, NPU ties
Advanced Micro Devices (AMD) CEO Lisa Su is reportedly set to visit South Korea again in October 2026, after her March 2